SAN DIEGO, Feb. 23, 2014 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased to announce that Dr. Alexandre Abizaid, co-principal investigator for REVA's RESTORE II clinical trial, is presenting information on the Company's bioresorbable scaffold program at the Cardiovascular Research Technologies (CRT) 2014 conference at 1:55 p.m. US EST on Monday, February 24, 2014. The conference is being held February 22nd through 25th at the Omni Shoreham Hotel in Washington, DC.
The presentation materials will be available in the Investor Relations section of REVA's website at www.revamedical.com on the day of the presentation.
About REVA
REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialization of its proprietary bioresorbable stent products. The ReZolve® product family, which is in a clinical study phase, combines REVA's proprietary stent design with a proprietary polymer that is metabolized and cleared from the body. REVA's anticipated initial commercial product, the ReZolve2 scaffold, is designed to offer full x-ray visibility, clinically relevant sizing, and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of scaffold structure over time, the ReZolve2 scaffold may reduce the incidence of late forming blood clots or otherwise reduce long-term disease progression, potential benefits of bioresorbable scaffolds that have yet to be proven. REVA will require clinical results and regulatory approval before it can begin selling the ReZolve2 scaffold or any of its future products.